{"brief_title": "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis", "brief_summary": "The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo", "condition": "Multiple Sclerosis", "intervention_type": "Drug", "intervention_name": "BMS 188667 (Abatacept)", "description": "Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months.", "arm_group_label": "3", "other_name": "Orencia", "criteria": "Inclusion - relapsing-remitting MS - at least 1 exacerbation in preceding 2 years - at least 1 MRI lesion - stable for 2 months prior to dosing Exclusion - progressive MS - currently treated with an immunomodulatory therapy - previously treated with an approved MS drug where treatment was discontinued for lack of efficacy - active bacterial or viral infections", "gender": "All", "minimum_age": "18 Years", "maximum_age": "55 Years", "healthy_volunteers": "No", "id": "NCT00035529.xml"}